VRXA today
$1.04+$0.01 (+0.97%)close Nov 20, 2026Trend
DailyNeutral
4 hourExpanding
1 hourStrong Bullish
15 minLeaning Bullish
5 minStrong Bearish
Key levels
Resistance$11.20
Resistance$10.01
Latest news & SEC filings
ProductVeraxa Biotech says lab tests support its BiTAC-ADC platform
SEC FilingVeraxa Biotech AG - Post de-SPAC filed an insider trading report (Form 4)
All VRXA news →About Veraxa Biotech
Veraxa Biotech is a clinical-stage biotechnology company developing antibody-based cancer therapies. Its pipeline includes antibody-drug conjugates built on Click Chemistry ADC platforms and bispecific T-cell engager (BiTAC) platforms, with lead candidate VX-A901 in development for acute myeloid leukemia. The company operates through a Swiss parent and a German subsidiary, and pursues collaborations and partnerships with third parties to advance its product candidates.
Based on the company's 20-F filed Jun 16, 2026.
Nasdaq · Healthcare
Veraxa Biotech AG - Post de-SPAC (VRXA)
What Is the Price Target for VRXA?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is VRXA a Buy or Sell Right Now?
Test your own strategy on VRXA
Describe your strategy in plain words, then scan, alert, backtest and paper trade it on VRXA with SEPT’s own market data.
Start Free Trial →Is VRXA Overvalued or Undervalued?
Valuation Verdict
N/A
Methods Used
N/A
Fair Value
$N/A
5
Moat Score
NONE
0/9
Piotroski Score
N/A
Altman Z-Score
What Is Smart Money Doing with VRXA?
Insider Signal
NEUTRAL
1 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Gruninger Marc | director | Buy | 9,133 | $9K | Oct 28, 2026 |
| Gruninger Marc | director | Buy | 867 | $849.66 | Oct 27, 2026 |
| Ziegler Christoph Samuel | director | Buy | 30,000 | $33K | Oct 20, 2026 |
| Hosseinion Warren | director | Buy | 6,024 | $10K | Sep 10, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See Smart Money Data →VRXA Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
N/A
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for VRXA
PREVIEWRecent off-exchange (dark pool) prints for VRXA: size, dollar value and side. One of the data views on SEPT, alongside its own pressure bars, swings, volume spike levels and key levels.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 16:40:22 | $1.04 | 7,000 | $$7K | SELL |
| 16:36:10 | $1.05 | 1,000 | $$1K | MIDPOINT |
| 16:01:43 | $1.03 | 1,000 | $$1K | SELL |
| 16:00:48 | $1.03 | 1,000 | $$1K | SELL |
| 15:59:36 | $1.03 | 1,000 | $$1K | SELL |
5 dark pool trades shown · $$11K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Veraxa Biotech AG - Post de-SPAC (VRXA) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Your strategy, tested before real money.
Describe your strategy in plain words. SEPT scans, alerts, backtests and paper trades it on its own market data. SEPT provides tools only and does not tell you what to buy or sell.
Try SEPT Free for 7 Days →VRXA — frequently asked questions
What is VRXA stock price today?
Veraxa Biotech AG - Post de-SPAC (VRXA) is at $1.04, up 0.97% (+$0.01) at the Nov 20, 2026 close.
Why is VRXA stock moving today?
Latest VRXA news — Nov 15, 2026: Veraxa Biotech says lab tests support its BiTAC-ADC platform · Oct 21, 2026: Veraxa Biotech AG - Post de-SPAC filed an insider trading report (Form 4)
What are VRXA support and resistance levels?
Resistance: $10.01, $11.20.
What are insiders doing with VRXA?
Insider activity: NEUTRAL, 1 buys and 0 sells in the last 90 days.
What is the latest news on VRXA?
Nov 15, 2026: Veraxa Biotech says lab tests support its BiTAC-ADC platform · Oct 21, 2026: Veraxa Biotech AG - Post de-SPAC filed an insider trading report (Form 4)